Early Access — free while we kick the tires
EdgarHawk

Booth Andrew

Chief Financial Officer

Officer
1 filing analyzed · 1 company · Latest 2026-02-27

Companies

Company Buys Sells Direction
AbCellera Biologics Inc. ABCL 1 0 Net buying

Activity

February 2026
high
Buy
42,600 shares
$145,692
Significance 7/10

CFO Andrew Booth purchases 42,600 shares of ABCL at $3.42, raising holdings to 195,600 shares amid -41.5% drawdown from 52-week high.

CFO Andrew Booth acquired 42,600 shares at $3.42 on 2026-02-27, increasing his position by 27.8% to 195,600 shares post-transaction. This purchase occurs as the stock trades at $3.61, down 41.5% from its 52-week high of $6.17, representing a sustained decline in valuation. The company is generating revenue growth of 160.6% year-over-year ($9.0M in the latest quarter) but remains deeply unprofitable with a full-year net income of -$57.1M, indicating significant ongoing losses despite rapid sales expansion. The timing coincides with substantial price depreciation, which may reflect elevated execution or profitability risk that the market is pricing in, warranting careful examination of whether the CFO's accumulation signals conviction in the company's path to profitability or represents exposure to continued operational headwinds.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access